Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the Literature
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is the most common entity of mature T-cell neoplasms. PTCL-NOS generally has an aggressive behavior and is often refractory to standard therapy. Only a few cases of PTCL with aberrant expression of B-cell antigens have been reported so f...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-05-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/10/6/341 |
| _version_ | 1827716186846003200 |
|---|---|
| author | Alessandro Mangogna Maria Christina Cox Luigi Ruco Gianluca Lopez Beatrice Belmonte Arianna Di Napoli |
| author_facet | Alessandro Mangogna Maria Christina Cox Luigi Ruco Gianluca Lopez Beatrice Belmonte Arianna Di Napoli |
| author_sort | Alessandro Mangogna |
| collection | DOAJ |
| description | Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is the most common entity of mature T-cell neoplasms. PTCL-NOS generally has an aggressive behavior and is often refractory to standard therapy. Only a few cases of PTCL with aberrant expression of B-cell antigens have been reported so far. This phenotypic aberrancy may lead to misdiagnosis as B-cell non-Hodgkin lymphomas and eventual inappropriate patient management, whereas in an accurately diagnosed PTCL, the presence of CD20 may appear as an appealing therapeutic target. In this setting, response to anti-CD20 monoclonal antibody in combination with chemotherapy has been poorly explored. We describe the case of a 59-year-old male diagnosed by a pathological and molecular approach as PTCL-NOS with aberrant co-expression of the B-cell antigens CD20 and CD79a, which proved non-responsive to the addition of rituximab to standard polychemotherapy. This case highlights that the presence of CD20 in PTCL may be misleading in the diagnosis and also act as a lure for the clinician to adopt a rituximab-based treatment, the effectiveness of which is undefined as the molecular mechanisms underlying B-cell marker expression in PTCL. |
| first_indexed | 2024-03-10T19:35:01Z |
| format | Article |
| id | doaj.art-ba5d09d5ad0b4c6681d60a1d65d9bd21 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T19:35:01Z |
| publishDate | 2020-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-ba5d09d5ad0b4c6681d60a1d65d9bd212023-11-20T01:47:19ZengMDPI AGDiagnostics2075-44182020-05-0110634110.3390/diagnostics10060341Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the LiteratureAlessandro Mangogna0Maria Christina Cox1Luigi Ruco2Gianluca Lopez3Beatrice Belmonte4Arianna Di Napoli5Pathology Unit, Clinical Department of Medical, Surgical and Health Science, University of Trieste, Cattinara Hospital, 34149 Trieste, ItalyHaematology Unit, Sant’Andrea Hospital, Sapienza University, 00189 Rome, ItalyPathology Unit, Department of Clinical and Molecular Medicine, Sant’Andrea Hospital, Sapienza University, 00189 Rome, ItalyPathology Unit, Department of Clinical and Molecular Medicine, Sant’Andrea Hospital, Sapienza University, 00189 Rome, ItalyTumor Immunology Unit, Human Pathology Section, Department of Health Sciences, University of Palermo, 90134 Palermo, ItalyPathology Unit, Department of Clinical and Molecular Medicine, Sant’Andrea Hospital, Sapienza University, 00189 Rome, ItalyPeripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is the most common entity of mature T-cell neoplasms. PTCL-NOS generally has an aggressive behavior and is often refractory to standard therapy. Only a few cases of PTCL with aberrant expression of B-cell antigens have been reported so far. This phenotypic aberrancy may lead to misdiagnosis as B-cell non-Hodgkin lymphomas and eventual inappropriate patient management, whereas in an accurately diagnosed PTCL, the presence of CD20 may appear as an appealing therapeutic target. In this setting, response to anti-CD20 monoclonal antibody in combination with chemotherapy has been poorly explored. We describe the case of a 59-year-old male diagnosed by a pathological and molecular approach as PTCL-NOS with aberrant co-expression of the B-cell antigens CD20 and CD79a, which proved non-responsive to the addition of rituximab to standard polychemotherapy. This case highlights that the presence of CD20 in PTCL may be misleading in the diagnosis and also act as a lure for the clinician to adopt a rituximab-based treatment, the effectiveness of which is undefined as the molecular mechanisms underlying B-cell marker expression in PTCL.https://www.mdpi.com/2075-4418/10/6/341peripheral T-cell lymphomaB-cell antigensCD20CD79arituximab |
| spellingShingle | Alessandro Mangogna Maria Christina Cox Luigi Ruco Gianluca Lopez Beatrice Belmonte Arianna Di Napoli Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the Literature Diagnostics peripheral T-cell lymphoma B-cell antigens CD20 CD79a rituximab |
| title | Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the Literature |
| title_full | Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the Literature |
| title_fullStr | Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the Literature |
| title_full_unstemmed | Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the Literature |
| title_short | Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the Literature |
| title_sort | rituximab plus chemotherapy provides no clinical benefit in a peripheral t cell lymphoma not otherwise specified with aberrant expression of cd20 and cd79a a case report and review of the literature |
| topic | peripheral T-cell lymphoma B-cell antigens CD20 CD79a rituximab |
| url | https://www.mdpi.com/2075-4418/10/6/341 |
| work_keys_str_mv | AT alessandromangogna rituximabpluschemotherapyprovidesnoclinicalbenefitinaperipheraltcelllymphomanototherwisespecifiedwithaberrantexpressionofcd20andcd79aacasereportandreviewoftheliterature AT mariachristinacox rituximabpluschemotherapyprovidesnoclinicalbenefitinaperipheraltcelllymphomanototherwisespecifiedwithaberrantexpressionofcd20andcd79aacasereportandreviewoftheliterature AT luigiruco rituximabpluschemotherapyprovidesnoclinicalbenefitinaperipheraltcelllymphomanototherwisespecifiedwithaberrantexpressionofcd20andcd79aacasereportandreviewoftheliterature AT gianlucalopez rituximabpluschemotherapyprovidesnoclinicalbenefitinaperipheraltcelllymphomanototherwisespecifiedwithaberrantexpressionofcd20andcd79aacasereportandreviewoftheliterature AT beatricebelmonte rituximabpluschemotherapyprovidesnoclinicalbenefitinaperipheraltcelllymphomanototherwisespecifiedwithaberrantexpressionofcd20andcd79aacasereportandreviewoftheliterature AT ariannadinapoli rituximabpluschemotherapyprovidesnoclinicalbenefitinaperipheraltcelllymphomanototherwisespecifiedwithaberrantexpressionofcd20andcd79aacasereportandreviewoftheliterature |